Diagnocure, Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a DGCRF research report →
About the company
Diagnocure, Inc. is a Canadian life sciences company dedicated to developing and commercializing innovative products for cancer diagnosis. Its core business revolves around advanced molecular diagnostic tests designed for the identification and management of cancerous conditions.
- CEO
- Yves Fradet F.R.C.S.,
- IPO
- 2009
- Employees
- 3
- HQ
- Quebec, QC, CA
Price Chart
- Market Cap
- $21.52K
- P/E
- -0.00
- P/S
- 0.06
- P/B
- 0.00
- EV/EBITDA
- 0.19
- Div Yield
- 0.00%
- Gross Margin
- 100.00%
- Op Margin
- -294.02%
- Net Margin
- -698.56%
- ROE
- -110.73%
- ROIC
- -102.04%
- Revenue
- $515.37K · -6.83%
- Net Income
- $-3,600,168 · -77.16%
- EPS
- $-0.11 · -96.08%
- Op Income
- $-1,515,318
- FCF YoY
- 38.07%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -15.95
- Avg Volume
- 2.57K
Get TickerSpark's AI analysis on DGCRF
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our DGCRF coverage
Recent articles, reports, and earnings notes.
No research on DGCRF yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate DGCRF report →Similar companies
Peers in the same neighborhood.